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Abstract
Background: The respiratory illnesses caused by influenza virus can be dramatically reduced by vaccination. The current
trivalent inactivated influenza vaccine is effective in eliciting systemic virus-specific antibodies sufficient to control viral
replication. However, influenza protection generated after parenteral immunization could be improved by the induction of
mucosal immune responses.
Methodology/Principal Findings: Transcutaneous immunization, a non-invasive vaccine delivery method, was used to
investigate the quality, duration and effectiveness of the immune responses induced in the presence of inactivated
influenza virus co-administered with retinoic acid or oleic acid. We observed an increased migration of dendritic cells to the
draining lymph nodes after dermal vaccination. Here we demonstrate that this route of vaccine delivery in combination with
certain immunomodulators can induce potent immune responses that result in long-term protective immunity.
Additionally, mice vaccinated with inactivated virus in combination with retinoic acid show an enhanced sIgA antibody
response, increased number of antibody secreting cells in the mucosal tissues, and protection from a higher influenza lethal
dose.
Conclusions/Significance: The present study demonstrates that transdermal administration of inactivated virus in
combination with immunomodulators stimulates dendritic cell migration, results in long-lived systemic and mucosal
responses that confer effective protective immunity.
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Introduction
Influenza infection and related complications result in thou-
sands of hospitalizations and deaths worldwide every year. In the
United States, there are currently two influenza vaccines licensed:
a trivalent inactivated influenza vaccine (TIV) and the live
attenuated influenza vaccine. The TIV induces mainly systemic
strain-specific humoral responses while the intranasally adminis-
tered live attenuated influenza vaccine generates mucosal humoral
responses, but its use is limited to people between the ages of 2–49.
A major hurdle in influenza prevention is its frequent antigenic
change, which evades the host’s acquired immunity[1,2] and
requires annual vaccination particularly of high-risk individuals.
Therefore, alternative vaccine formulations, adjuvantation and
routes of delivery are being investigated to create a more
efficacious vaccine that would induce long-lived mucosal and
systemic immune responses with broader cross-protection.
The skin is an immunologically active organ[3] where large
numbers of antigen presenting cells (APCs), mainly Langerhans
cells and dermal dendritic cells, reside. These populations form an
integral part of the innate immune system, which upon antigen
stimulation can prime and provide an amplified signal to the cells
of the adaptive immune system[4]. The presence of APCs in high
density and the skin accessibility make it an ideal target for vaccine
delivery. APCs upon antigen uptake mature in response to
inflammatory signals and migrate to the regional draining lymph
nodes where they present antigen to T and B cells and initiate the
adaptive immune responses[4,5,6,7,8].
Transcutaneous immunization (TCI) is a needle-free approach
that involves the application of vaccine and often adjuvant to the
skin surface. It is a simple, cost effective and fairly safe vaccine
delivery method that may offer the additional advantages of self-
administration. TCI successfully generates immunity not only with
soluble proteins but also with large molecules such as particulate
antigens despite the tight structure of the epidermis[9,10],
inducing mucosal and systemic immune responses as well as
protection against viral infection[11,12,13,14,15,16,17,18]. We
have previously demonstrated that retinoic acid, oleic acid and
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the immune response to transdermal [18]. Their capacity to
increase the antigenic response when applied through the dermis
demonstrate that they serve as bona fide adjuvants. A highly
effective adjuvant should enhance both the magnitude and
duration of the immune response against a particular patho-
gen[19].This principle is fundamental for protection against
pathogens encountered long after immunization. In the present
study we investigated these fundamental properties of transdermal
vaccination and we report the effect of these immunomodulators
on the duration of the immune response and their efficacy in
generating protective immunity.
Materials and Methods
Reagents
Cholera toxin (CT) and oleic acid (OA) were purchased from
Sigma-Aldrich (St. Louis, MO) and retinoic acid (RA) from Alexis
Biochemicals (San Diego, CA). Purified mouse IgG, IgG1, and
IgG2a antibodies were obtained from Southern Biotech (Birming-
ham, AL). ELISPOT reagents were purchased from BD-PharMin-
gen and ELISA reagents from eBiosciences (San Diego, CA). Stable
diaminobenzidine (DAB) was obtained from Research Genetics
(Carlsbad, CA) and Tegaderm patches from 3M (Minneapolis,
MN). Receptor-destroying enzyme was purchased from Roche
Diagnostics (Indianapolis, IN). All H-2
d–restricted Class I and
II peptides were synthesized by the Emory University Peptide
Facility. H-2
d-restricted Hemagglutinin (HA) Class II peptides
(SFERFEIFPKE, HNTNGVTAACSH, CPKYVRSAKLRM,
KLKNSYVNKKGK, and NAYVSVVTSNYNRRF) and H-2
d-
restricted HA class I peptide (LYEKVKSQL) were used at 1 mg/m.
Nucleoprotein (NP) H-2
d-restricted class I peptide (TYQRTRALV,
was used at 0.5 mg/ml and a pool of three H-2
d-restricted class II
peptides (FWRGENGRKTRSAYERMCNILKGK, RLIQNSL-
TIERMVLSAFDERNK, and AVKGVGTMVMELIRMIKR-
GINDRN) at 1 mg/ml[20,21].
Virus preparation
Influenza virus was prepared by inoculation of 10- or 11-day old
embryonated hen’s eggs with 2-5 HA units/egg of A/PR8/34
(PR8, H1N1). The hemagglutination (HA) activity was determined
as previously described[22]. The virus was purified from allantoic
fluid in discontinuous sucrose gradient as previously described
[18]. Virus purification was followed by inactivation with formalin
(0.01%) (vol/vol) for 72 hrs at 4uC, and dialyzed against PBS as
described (ref). The protein concentration of the inactivated virus
stock was determined by Bio-Rad Protein Assay. Inactivation was
confirmed by inoculation of the virus into 10-day-old embryonated
hen’s eggs and plaque assay[23].
Immunization
The dorsal caudal surface of twelve female BALB/C mice per
group (Charles River Laboratory) was prepared for TCI as
previously described [18]. RA and OA were co-administered with
PR8 at concentrations of 50 mg/100 ml in 70% ethanol and 1%
(w/v) in 70% ethanol respectively over an area of 1 cm
2. Fifty ml
of inactivated PR8 (100 mg) or with CT (100 mgi n5 0ml) was
applied to the skin and covered with a Tegaderm patch. Three
TCI doses were administered 3 weeks apart. A group of mice were
intranasally (i.n.) immunized at the same time intervals with
inactivated PR8 (50 mgi n5 0ml) as controls. Two separate cohorts
were used for the evaluation of in vitro cellular immune responses 2
weeks after the 3d immunization dose immunization and for the
duration of the humoral responses 12 weeks after the completion
of the vaccination regimen. The animal protocols were performed
in accordance with Emory’s Institutional Animal Care and Use
Committee guidelines.
Influenza virus challenge
To determine post-challenge survival rates and perform
immune assays, mice were challenged 12 weeks post-immuniza-
tion by intranasal instillation of 5XLD50 or 20xLD50 of live mouse
adapted A/PR/8/34 virus in 25 ml and monitored for morbidity
based on body weight loss for 10 days. For lower infectious doses
used in Table 1, the same mouse adapted A/PR/8/34 was used
i.n. at 1xLD50 and 2xLD50 (300 and 600 PFU respectively). A
mouse weight loss of over 25% was used as the experimental end-
point. The survival data were reported using the Kaplan-Meier
method. The mice that survived the infection were bled at the end
of the monitoring period to assess the antibody response.
Evaluation of humoral immune responses
Influenza-specific IgG, IgG1, IgG2a and IgA titers were
determined in the sera and bronchoalveolar lavage fluid (BALF)
of mice by enzyme linked immunosorbent assay (ELISA) as
previously described[24].
Neutralization assay
Sera were serially diluted and mixed with 100 pfu of PR8 virus,
added to a MDCK cell monolayer and incubated for 1 hr at 37uC.
The inoculum was removed, wells were overlayed with DMEM
agar and incubated for 4 days at 37uC in a 5% CO2 humidified
incubator. Then, plates were fixed with 0.25% gluteraldeyde and
stained with 1% crystal violet in 20% ethanol, and plaques were
counted[25,26]. Neutralizing antibodies titers were determined as
the reciprocal of the serum dilution that decreased by 50% the
number of plaques formed by the live virus.
Table 1. Serum influenza-specific IgG titers.
Groups IgG (ng/ml)
PBS 93.7631.8
PR8 2043.06131.1
PR8-OA-RA 3170.06262.7
a
PR8-CT 3884.36111.1
a
PR8-CT-RA 6205.96432.9
a,b,c
PR8-CT-OA 6599.46881.6
a,b
PR8 i.n. 7598.46705.8
a,b,c
1xLD50 4785.96384.3
2xLD50 8104.562087.1
Serum anti-influenza IgG antibody titers. Serum influenza specific IgG titers
(ng/ml). The immunized mice (6 animals per group) were bled 2 weeks after
immunization. Two groups of naı ¨ve mice were infected with 1xLD50 and 2xLD50
of live A/PR/6/34 and bled 8 days after infection. PBS, mock immunized mice
with PBS were used as a negative control. TCI groups; PR8, inactivated influenza
virus; PR8-OA-RA, virus co-administered with OA and RA; PR8-CT, inactivated
influenza virus plus CT; PR8-CT-RA, inactivated influenza with RA and CT and;
PR8-CT-OA, inactivated influenza virus and co-administration of OA and CT; PR8
i.n., intranasal immunization with 50 mg of inactivated virus as a positive
control. Data shown are average and standard deviation (S.D.) from 6 mice per
group. Statistics;
a: p,0.05 comparing all groups to the PR8 alone group,
b: ,0.05 comparing adjuvanted groups to PR8-CT group (PR8-CT-RA, PR8-CT-
OA, PR8-OA-RA) and
c: p,0.05, comparing all immunized groups to 1xLD50 infected group.
doi:10.1371/journal.pone.0010897.t001
Intradermal Immunization
PLoS ONE | www.plosone.org 2 May 2010 | Volume 5 | Issue 5 | e10897Evaluation of cellular immune responses
Cellular immune responses were assayed by ELISPOT of spleen
cellspreparedfrommicetwoweekspostimmunization.0.5–1.0610
6
splenocytes/well in complete RPMI 1640 medium (cRPMI: with
10% FBS, 10 mM L-glutamine, nonessential amino acids, HEPES
buffer, and penicillin/streptomycin) were cultured for 36 hours in
the presence of 0.5–1 mg/ml peptide stimulants, as described[27].
The number of cytokine producing lymphocytes was determined as
described[24]. Briefly, multiscreen 96-well filtration plates were
coated with IL-4 and IFN-c capture antibodies at 4uC overnight
and were blocked with 10% FBS in RPMI for 2 hr at 37uC.
Splenocytes (1.0610
6/200 ml) were mixed with either HA immu-
nogens (H-2
d-restricted HA Class II peptides or one H-2
d-restricted
HA class I peptide) or NP immunogens (NP class II peptides or NP
class I peptide) and plated in duplicates for 36–40 hrs. Biotinylated
anti-mouse IL-4 or IFN-c antibodies, streptavidin-HRP (horse-
radish peroxidase) and DAB were used for detection. Spots were
counted in an ELISPOT reader (Cellular Technology, Shaker
Heights, OH).
Antibody-secreting cell analysis
Virus-specific antibody-secreting cells (ASC) in the lungs and
spleens of mice were evaluated at day 4 post-challenge (with
5xLD50 PR8) by a modification of the ELISPOT assay[28].
Briefly, 96-well plates were coated overnight at 4uC with 4 mg/ml
of inactivated PR8 virus, washed and blocked for 2 h with 10%
FBS. Single cell suspensions (1610
6/well) were plated and
incubated at 37uC for 18 h. Positive spots were labeled with goat
anti-mouse IgG HRP (Southern Biotech) and developed with DAB
substrate. An ELISPOT reader was used to enumerate samples in
triplicates and values were reported as the mean ASCs per 10
6
cells.
Cell trafficking
Inguinal lymph nodes were collected from sacrificed mice 2.5
days after application of the antigen 6 adjuvant(s) to the dorsal
skin. Single cell preparations were prepared as described [29] and
stained with rat anti mouse CD205 Alexa 488 (Serotec), anti-
CD11c PE, anti-CD11b APC and anti-CD8a+ PercP (BD-
Pharmingen). Triple positive populations were considered den-
dritic cells and the percentage of total gated CD11c+/CD11b+/
CD205+ cells was analyzed using FlowJo software.
Statistics
We used one way or two way ANOVA test for comparison of
parameters between groups and a value of p#0.05 was considered
significant. Unless otherwise stated, data are representative of at
least three independent experiments.
Results
Humoral response enhancement by immunomodulators
We investigated whether mice transcutaneously immunized
with influenza virus generated antibody titers similar to those
observed after an influenza viral infection. Groups of mice
received either inactivated PR8 virus alone (PR8) or combined
with RA and OA (PR8-OA-RA), CT (PR8-CT), CT and RA
(PR8-CT-RA) or CT and OA (PR8-CT-OA) and were compared
to groups of mice that survived infection by intranasal instillation
of 1xLD50 or 2xLD50 of mouse adapted PR8 virus. To assess the
efficacy of TCI we used as control group immunized mice
immunized intranasally with formalin inactivated influenza virus
(PR8 i.n.)[30]. The mice that survived the challenge were tested
2-weeks post-infection for serum PR8-specific IgG antibodies and
the titers were compared to those from immunized mice. The co-
administration of RA or OA with PR8 and CT induced
comparable antibody titers to the group infected with 2xLD50,
indicating that TCI with inactivated influenza virus is capable of
eliciting strong immune responses at similar levels to those
obtained following virus infection (Table 1). In particular, the
addition of retinoic acid to the PR8-CT regimen induced
statistically significant higher antibody titers when compared to
the group infected with 1xLD50 (P=0.01). To confirm the
generation of functional antibodies, we assayed the potential of
the sera obtained from the immunized groups to neutralize viral
replication in vitro. The highest neutralizing antibody titers were
observed in the PR8-CT-RA group as seen by the 50% plaque
reduction at a 2,560 serum dilution. The rest of the adjuvanted
groups demonstrated 50% virus neutralization at a 1,280 dilution
whereas the PR8 group showed the lowest neutralizing titers (640
dilution) (Figure 1). Some correlation was observed between the
percent survival and the neutralizing titers. Although the PR8-CT
and PR8-CT-OA groups were less effective than the PR8-CT-RA
group in virus neutralizing activity (40% vs 50% plaque reduction
at 2,560 dilution) their differences were not statistically significant.
These data support the trend observed that when retinoic acid is
used in combination with cholera toxin enhances the protective
immune response.
In order to assess the cellular immune responses generated after
immunization we performed an in vitro re-stimulation of spleno-
cytes from vaccinated mice with Class I and II H-2
d restricted
hemagglutinin (HA) or nucleoprotein (NP) peptides. IFN-c
producing cells were increased by 3 to 8-fold in the PR8-OA-
RA and PR8-CT-OA groups that were re-stimulated with Class I
restricted HA peptides when compared to the TCI PR8 group.
These differences were not statistically significant but the numbers
of IFN-c producing cells were similar to those generated in the i.n.
immunized control group (Figure 2A). This observation suggests a
higher generation of effector T cells by these adjuvants. The
differences were more pronounced upon HA Class II restricted
re-stimulation, after which the PR8-CT-RA and PR8-CT-OA
Figure 1. Neutralizing antibody titers after vaccination. Virus-
neutralizing antibody activities in sera collected 2 weeks after
immunization. Dilutions of sera were incubated with approximately
100 plaque forming units of PR8 virus for 1 hr at room temperature,
applied to monolayers of confluent MDCK cells, and a standard plaque
reduction assay was performed. Representative data are shown from at
least three independent experiments. Data shown are average and
standard error of mean (SEM) from 6 mice per group. Groups are as
described in legend of Table 1.
doi:10.1371/journal.pone.0010897.g001
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producing cells compared to both PR8 (P=0.0004 and
P=0.0095, respectively) and PR8-CT groups (P=0.0003 and
P=0.0197, respectively)(Figure 2B). The re-stimulation of spleno-
cytes with HA Class I restricted peptides did not induce any
statistically significant differences in the numbers of IL-4
producing cells among vaccinated groups, but showed enhanced
responses in the PR8-CT-RA and PR8-CT-OA TCI groups when
HA Class II restricted peptides were used (Figure 2A,B).
Additionally, these groups showed a robust IFN-c production
similar to what observed after i.n. immunization. When we
assessed the NP specific responses in vitro, due to the high
variation in the number of IFN-c producing cells we did not
observed a distinction between the TCI groups. Similarly, the re-
stimulation of splenocytes with NP Class I peptides lacked
statistically significant differences in the numbers of IL-4
producing cells among the vaccinated groups (Figure 2C). In
contrast, splenocytes re-stimulated with NP Class II peptides
showed a marked increase of IL-4 producer cells in most
adjuvanted groups as compared to the naı ¨ve or PR8 groups
(P=0.0013, 0.017 and 0.012 for PR-OA-RA, PR8-CT and PR8-
CT-RA respectively) (Figure 2D).
Our data demonstrate that the PR8-CT co-administration of
retinoic acid or oleic acid with induces marked increases in the
numbers of IFN-c producing CD4+ and CD8+ effector cells which
correlate with effective viral clearance upon lethal challenge.
Protective immunity to live virus challenge
Since TCI mice demonstrate robust humoral and cellular
immune responses two weeks after vaccination, we evaluated the
Figure 2. IL-4 and IFN-c secreting cells in response to inactivated influenza antigen. The cellular immune responses were analyzed in
splenocytes by ELISPOT for IL-4 and IFN-c production 2 weeks after vaccination by re-stimulation with nucleoprotein (NP) and hemagglutinin (HA)
class I (A,B) and class II (C,D) restricted peptides. Groups are as described in the legend of Table 1. Data are pooled from three independent
experiments and are the average 6 SEM for six mice per group. Statistical significance of the differences between groups in comparison was
calculated by Student’s test (p,0.05). Statistics; a: p,0.05 comparing all groups to the PR8 alone group, b: ,0.05 comparing adjuvanted groups to
PR8-CT group (PR8-CT-RA, PR8-CT-OA, PR8-OA-RA).
doi:10.1371/journal.pone.0010897.g002
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adapted influenza virus 12 weeks post-vaccination. The group of
naı ¨ve mice infected with 5xLD50 of PR8 virus lost 25% of their
body weight between days 5 and 7 and were euthanized. In
contrast, TCI conferred protection with 100% survival in all PR8
vaccinated groups (Figure 3A). The TCI mice showed minimal
weight loss and minimal to no morbidity signs during the
evaluation period. To highlight the possible differences among
the adjuvants used, we challenged a second cohort of mice with a
4-fold higher influenza lethal dose (20xLD50). We found that
100% of the mice immunized with PR8-CT-RA survived. Partial
protection was observed in the remaining groups, whereas the
naı ¨ve mice died between day 5 and 6 (Figure 3B). The percent of
survival was tightly correlated with the percentage of body weight
recovery suggestive of a milder disease in the groups with reduced
mortality (Figure 3C).
Systemic and mucosal humoral immune responses after
lethal challenge
Since transcutaneous immunization for most adjuvanted groups
induced antibody titers as efficiently as live virus infection, we
characterized the type of humoral response induced twelve weeks
post-vaccination in mice challenged with 5xLD50 of mouse
adapted PR8 virus. We studied the induction of serum PR8-
specific IgG antibodies and the antibody isotype levels on days 4
and 8 after challenge. On day 4 post-challenge the differences
observed in the IgG titers were not statistically significant, but we
observed higher titers in the PR8-CT-RA relative to the other TCI
groups (Figure 4A). By day 8, the IgG titers from all groups of TCI
mice were increased similarly by 4-fold, reaching approximately
60% of levels observed by i.n. immunization (Figure 4A).
Differences in the systemic responses between the groups were
observed in the antibody profiles generated. Immunoglobulin
subtype IgG1 and IgG2a titers were evaluated due to their role in
complement activation and because they are indicators of the
cytokine environment in which the antibody response is generated
[31,32,33]. We observed that at both time points after challenge
the predominant responses against influenza antigen were of the
IgG1 isotype (Figure 4B,C,D)[18] and that the use of CT, and
particularly CT-RA, enhance the IgG2a isotype to the highest
levels among the TCI groups. The presence of higher IgG2a titers
was a common factor observed within the groups that showed a
higher percent survival after lethal challenge. The generation of
both IgG1 and IgG2a influenza specific antibodies in the groups
that received CT and by intranasal immunization may have also
contributed to the enhanced viral neutralization observed in these
groups.
It has been reported that intranasal or dermal immunization
induces effective mucosal immune responses, which have an
important role in controlling viral replication in the respiratory
system [34,35,36,37]. In view of this, we assessed whether TCI
enhanced the response in the bronchoalveolar lavage fluid (BALF)
after challenge. The mucosal sIgA titers at 4 days post-challenge
showed low levels of antibody production and with the exception
of the PR8 i.n. group were similar to that observed in the PBS
vaccinated control group (Figure 4E). Eight days post challenge we
detected an increase in the sIgA levels in the TCI groups in which
the immune enhancers OA and/or RA were co-administered. The
increased IgA titers found by RA co-administration reached 50%
of the titers induced by intranasal immunization (Figure 4E).
Notably, in the RA treated groups the mucosal IgG titers increased
substantially and appeared earlier (day 4) compared to the rest of
the TCI groups suggestive of an RA-induced seroconversion in the
mucosal tissue (Figure 4F).
Figure 3. Protection of mice from lethal influenza virus
challenge. Survival rates of immunized mice were monitored for 10
days after i.n. infection with mouse adapted PR8 virus. (A) Kaplan-Meier
curve showing the percent of mice that survived a 5x LD50 PR8 virus
challenge. (B) Percent of mice that survived a 20x LD50 PR8 virus
challenge. (C) Percentage of body weight after i.n. challenge with 20x
LD50 PR8 virus. PBS, PR8, PR8-OA-RA, PR8-CT, PR8-CT-OA, and PR8-CT-
RA groups are as described in the legend of Table 1. Data represent the
average of six mice per group for each challenge study.
doi:10.1371/journal.pone.0010897.g003
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TCI mice resulted in an increase of the number of antibody
secreting cells (ASC) and their recruitment to the mucosal tissue,
single cell suspensions from the spleen and lung tissue were used to
identify influenza-specific ASC by ELISPOT assay. We found that
TCI induces the generation of ASC in the spleen and that the
Figure 4. Antibody titers of post-challenged mice 4 and 8 days after intranasal infection with live A/PR/8/34 influenza virus. Total
IgG anti-influenza titers determined by quantitative ELISA from immunized mice. Serum IgG1 and IgG2a isotype titers at day 4 (B,D) and day 8 (C,D)
post-challenge. Ratios for IgG1/IgG2a were derived from the results in panels B and C. Mucosal IgA (E) and IgG (F) antibody titers by ELISA in
bronchoalveolar lavage fluid (BALF) at day 4 and 8 after challenge. Data shown are average and standard error of mean (SEM) from 6 mice per group.
Groups are as described in the legend of Table 1. Statistics; a: p,0.05 comparing all groups to the PR8 alone group.
doi:10.1371/journal.pone.0010897.g004
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their total number (Figure 5A,B). In addition, influenza-specific
ASC were found as early as 4 days post- infection in the lungs of
the immunized mice. The number of lung ASC was significantly
increased in the PR8-CT-RA group when compared to the mice
vaccinated with PR8 or PR8-CT.
Taken together, these results demonstrate that the immune
responses persisted 12 weeks post-TCI and that the levels of PR8-
specific antibody titers correlate with an increase of total ASC in
the lungs. Moreover this study shows that PR8 co-administration
of RA or OA in combination with CT results in the enhancement
of mucosal immune responses.
Enhanced mobilization of skin-associated dendritic cells
(DC). In order to better understand the mechanism of enhanced
immune responsiveness observed, we determined whether TCI
increased the migration of DC to the draining LN (Fig. 6). In view
of the fact that DCs are equipped with multiple surveillance
mechanisms and their activation is important to initiate the
adaptive immune response, we evaluated migration of these cells
to the draining LNs as an indication of increased antigen
presentation and establishment of adaptive immunity [38,39].
We administered inactivated influenza virus along with CT, OA
or RA by TCI individually or in combination, and identified DC
skin emigrants in the draining LNs by the expression of CD11c+/
CD11b+/CD205+ surface markers [40,41]. Mice immunized with
PR8-CT-RA showed the highest numbers in LN of mice when
compared with PR8. Interestingly, the PR8-CT-RA group
increased the numbers of skin derived DC by 2.5-fold when
compared to the PR8/CT indicating a synergistic effect (p,0.05).
These data show that TCI promotes migration of skin-resident
DC, and that the co-administration of CT and RA results in an
enhanced stimulatory effect on this mobilization.
Discussion
The present report demonstrates the potential of retinoic acid in
combination with cholera toxin as potent immunomodulators in
the protective responses induced by transcutaneous immunization
with whole inactivated influenza virus. Although all TCI groups
fully survived a 5xLD50 lethal dose, the only group that was
completely protected against a high infectious dose was the PR8-
CT-RA group. We observed that the use of cholera toxin in
combination with retinoic acid or oleic acid as immunomodulators
resulted in a seroconversion as robust as that observed following
infection by live virus. The co-administration of CT and RA
induced the highest neutralizing antibody titers, which is an
important correlate of viral clearance and protection. Retinoic
acid and OA also generated a robust cellular response as indicated
by the increased numbers of IFN-c secreting CD4+ and CD8+ T
cells. The combination of CT with OA and mainly RA revealed
that they were very effective as enhancers of mucosal and systemic
Figure 5. Influenza specific antibody secreting cells (ASC) in
spleen and lungs of immunized mice. (A) Splenocytes and (B)
single cell lung suspensions of vaccinated and control mice were
assessed by ELISPOT 4 days post-challenge. Data shown are average
and standard error of mean (SEM) from 5 mice per group. Groups are as
described in the legend of Table 1. N: naı ¨ve (unimmunized) mice; PBS:
mock immunized with PBS, challenged mice. Statistics; *: p,0.05
comparing all groups to the naive group;**: p,0.05 comparing all
groups to the PBS alone group; a: p,0.05 comparing all groups to the
PR8 alone group; b: ,0.05 comparing adjuvanted groups to PR8-CT
group (PR8-CT-RA, PR8-CT-OA, PR8-OA-RA).
doi:10.1371/journal.pone.0010897.g005
Figure 6. Dendritic cell mobilization to the lymph nodes upon
TCI immunization. Dendritic cells were gated as triple positive
populations (CD11c+/CD11b+/CD205+ cells). The total number of triple
positive population/mouse lymph node was calculated and the data of
each group of mice were averaged. Groups are as described in the
legend of Table 1.
doi:10.1371/journal.pone.0010897.g006
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group induced the highest systemic IgG2a titers among all groups
and its addition accelerated the generation of mucosal IgG titers as
seen in the PR8-CT-RA and PR8-OA-RA groups as early as 4
days post-challenge. The antibody titers induced by TCI
correlated tightly with an increase of ASC. In particular, the
PR8-CT-RA group showed the highest frequency of ASC in the
mucosa which may have been critical in the 100% survival
observed after challenge with a high lethal dose of mouse adapted
virus.
Using the mouse model we found that TCI even in the absence
of an adjuvant could induce robust recall B cell responses 12 weeks
after immunization, which are considered critical in generating
protective immunity[42]. The increase in serum IgG titers at day 4
post-infection suggests that this form of delivery generates
persistent B cell responses that rapidly produce virus-specific
antibodies. Although, the specific role of the antibody isotypes in
influenza virus neutralization remains to be fully elucidated, we
observed that in addition to the dominant IgG1 response normally
described in dermal immunization[43], the co-administration of
CT, RA and OA increased the production of IgG2a antibodies.
Correspondingly, the groups that exhibited higher survival rates
including the intranasally immunized group showed induction of
influenza specific IgG2a antibodies.
The transdermal co-administration of CT and RA enhanced
the mucosal antibody immune responses when compared to the
rest TCI groups. In particular, influenza specific lung IgG titers
were induced earlier and to comparable levels to the i.n. group.
This finding is significant since protective mucosal responses are in
general most effectively induced by mucosal immuniza-
tion[44,45,46]. Importantly, the observed increase in antibody
titers correlated with higher number of ASC in the lungs, which
indicates an enhanced recruitment of B cells to the mucosal tissue.
Based on these observations, we postulate that the enhanced lung
humoral responses result from the RA effect in the imprinting of T
and B cells to the mucosal tissue [47,48,49]. These results correlate
with the complete protection of the PR8-CT-RA group against
high infectious doses of influenza virus. Overall, we observed
strong recall immune responses when CT, OA and RA were used
as adjuvants or immunomodulators in transdermal vaccination.
The precise mechanism for inducing robust immune responses
by an antigen delivered to the skin is not well understood. It has
been postulated that the various dendritic cell populations residing
in the epidermis, following immunization and antigen uptake,
become activated and migrate to the regional lymph nodes where
they present antigens to naı ¨ve T and B cells resulting in adaptive
immune responses [11,13,16,23,50]. We observed that the co-
administration of PR8-CT and OA or RA significantly increased
mobilization of dendritic cells, which could influence T cell
differentiation and cytokine secretions. We found high numbers of
skin derived DCs in the draining LN implying their activation after
antigen application [36]. This mobilization was particularly
enhanced in the PR8-CT-RA group, corresponding to the group
with a higher survival rate. Our data suggest that this stronger
triggering of DC may have resulted in the effective adaptive
immunity observed. Elucidating the downstream sequence of
events and mediators involved in the observed enhancement of
immune responses is of interest for further investigation.
In summary, the results support the conclusion that a
transcutaneous influenza vaccine that employs a potent adjuvant
as cholera toxin in combination with an immune enhancer such as
RA induces increased humoral and cellular immune responses
required for successful protection against influenza virus challenge.
Most importantly, the present study suggests that the use of the
appropriate adjuvant or immunomodulatory molecule could
improve the efficacy of mucosal responses and could be utilized
against other mucosal pathogens.
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